Analysis of efficacy and safety of abatacept for rheumatoid arthritis: systematic review and meta-analysis
Authors' conclusion
This meta-analysis concludes that in adult with rheumatoid arthritis, abatacept can achieve better health outcomes than other biologic drugs.
Study context
- Population
- Adults with RA from different geographic regions and races
- Participants
- 5,978 adults13 RCTs
- Comparison
- Abatacept vs placebo, csDMARDs and/or other bDMARDs
- Outcome
- ACR 20/50/70/90 responses, abatacept vs placebo, csDMARDs and or other biologic DMARDs
Methodological detailsCochrane systematic review, PRISMA 2020
- Cochrane systematic review
- PRISMA 2020
Pooled result
As reported in the abstract
RR for ACR20 response
1.57
95%CI 1.27, 1.93
RR for ACR50 response
1.84
95%CI 1.38, 2.44
RR for ACR70 response
2.36
95%CI 1.60, 3.47
RR for ACR90 response
2.95
95%CI 1.88, 4.63
Further pooled results
- Better American College of Rheumatology (ACR) responses with abatacept than with other b/tsDMARDs
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Analysis of efficacy and safety of abatacept for rheumatoid arthritis: systematic review and meta-analysis. Clin Exp Rheumatol. Published 4 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →